Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service thrombectomy, IVC filters & venous stents cases in Delaware: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 9% on average (194 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 4 | 254 | 18% |
| 2020 | 2 | 185 | 20% |
| 2021 | 3 | 223 |
Mechanical thrombectomy, IVC filter placement, and iliac venous stenting. Professional codes (what the surgeon bills): CPT 37187, 37184, 37191, 37238.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Delaware; 2 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Peripheral arterial intervention | 8 | 910−1%/yr | −1%/yr | 5.20.8× | 79% | 2,020 in 2030+14%/yr |
| Dialysis access |
Thrombectomy, IVC filters & venous stents in every state, and its device makers · Every procedure market in Delaware · Every state · Compare with Florida
| ≈ 540 |
| – |
| 2026 est. | ≈ 600 | – |
| 25% |
| 2022 | 1 | 180 | 29% |
| 2023 | 0 | 162 | 32% |
| 2024 | 2 | 241 | 35% |
| 2025 from claims | – | 542 438–637 | 35% |
| 2026 forecast | – | 598 469–751 | 35% |
| 2027 forecast | – | 653 484–863 | 36% |
| 2028 forecast | – | 713 505–984 | 36% |
| 2029 forecast | – | 778 529–1,116 | 37% |
| 2030 forecast | – | 849 556–1,260 | 37% |
In 2025, 56% inpatient hospital, 44% office. The share outside the hospital has moved +34 pts since 2019, so more of this market is decided in surgery centers and offices each year.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| 4,117+1.6%/yr |
| +1.6%/yr |
| 1.9 |
| 17% |
| 6,020 in 2030+6.5%/yr |
| Maryland | 20 | 1,433−0.5%/yr | −0.5%/yr | 1.6 | 45% | 1,430 in 20300%/yr |
| Georgia | 9 | 1,269−2.2%/yr | −2.2%/yr | 1.5 | 9% | 1,580 in 2030+3.7%/yr |
| Tennessee | 12 | 1,232−0.4%/yr | −0.4%/yr | 1.8 | 20% | 1,220 in 2030−0.1%/yr |
| North Carolina | 4 | 1,069−0.8%/yr | −0.8%/yr | 1.1 | 0% | 1,460 in 2030+5.4%/yr |
| Virginia | 4 | 1,041−5.6%/yr | −5.6%/yr | 1.0 | 2% | 1,720 in 2030+8.7%/yr |
| South Carolina | 11 | 893+4.8%/yr | +4.8%/yr | 1.3 | 2% | 1,290 in 2030+6.4%/yr |
| Alabama | 7 | 675−4.4%/yr | −4.4%/yr | 1.6 | 12% | 640 in 2030−1%/yr |
| Arkansas | 6 | 614+8.4%/yr | +8.4%/yr | 1.6 | 5% | 680 in 2030+1.8%/yr |
| Oklahoma | 3 | 598+2.9%/yr | +2.9%/yr | 1.2 | 0% | 860 in 2030+6.2%/yr |
| Kentucky | 3 | 595+3.1%/yr | +3.1%/yr | 1.3 | 5% | 810 in 2030+5.2%/yr |
| Louisiana | 4 | 589−13%/yr | −13%/yr | 1.5 | 0% | 560 in 2030−0.8%/yr |
| Mississippi | 6 | 554+0.1%/yr | +0.1%/yr | 1.5 | 4% | 570 in 2030+0.6%/yr |
| West Virginia | 2 | 251−3%/yr | −3%/yr | 1.2 | 0% | 280 in 2030+1.6%/yr |
| District of Columbia | 1 | 238−4.9%/yr | −4.9%/yr | 3.8 | 10% | 210 in 2030−1.8%/yr |
| 7 |
| 781−12%/yr |
| −12%/yr |
| 4.70.8× |
| 89% |
| 780 in 20300%/yr |
| Superficial venous ablation | 7 | 284−5.2%/yr | −5.2%/yr | 1.60.3× | 100% | 440 in 2030+7.4%/yr |
| Carotid revascularization | 10 | 186−2.9%/yr | −2.9%/yr | 1.10.8× | 0% | 180 in 2030−0.6%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Penumbra leads with 63% of company spending on these surgeons in 2025, +51 pts on 2024.
In 2025, 11 companies reported engagement with Delaware’s surgeons worth $19K in consulting, speaking, meals and travel tied to these products, about $9,287 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 22 clearances and approvals in the category, 3 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.